Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Nektar Therapeutics (NKTR) and GE Healthcare Technologies Inc (GEHC)

Tipranks - Tipranks - Wed Apr 22, 6:02AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB), Nektar Therapeutics (NKTR) and GE Healthcare Technologies Inc (GEHC).

Claim 30% Off TipRanks

Biogen (BIIB)

BTIG analyst Thomas Shrader maintained a Hold rating on Biogen yesterday. The company’s shares closed last Monday at $183.34.

According to TipRanks.com, Shrader is a 4-star analyst with an average return of 8.8% and a 43.3% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Alto Neuroscience, Inc., Coya Therapeutics, Inc., and Acumen Pharmaceuticals. ;'>

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $208.78, implying a 16.3% upside from current levels. In a report issued on April 10, Morgan Stanley also maintained a Hold rating on the stock with a $200.00 price target.

See today’s best-performing stocks on TipRanks >>

Nektar Therapeutics (NKTR)

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Nektar Therapeutics, with a price target of $178.00. The company’s shares closed last Monday at $100.35.

According to TipRanks.com, Harrison is a top 100 analyst with an average return of 47.0% and a 57.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Mereo Biopharma Group Plc. ;'>

Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $135.25, representing a 38.7% upside. In a report issued on April 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $135.00 price target.

GE Healthcare Technologies Inc (GEHC)

BTIG analyst Ryan Zimmerman maintained a Buy rating on GE Healthcare Technologies Inc today and set a price target of $85.00. The company’s shares closed last Monday at $74.15.

According to TipRanks.com, Zimmerman is a 2-star analyst with an average return of 0.6% and a 42.8% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Shoulder Innovations, Inc., Tactile Systems Technology, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on GE Healthcare Technologies Inc is a Moderate Buy with an average price target of $89.50, representing a 20.9% upside. In a report issued on April 7, TipRanks – PerPlexity also upgraded the stock to Buy with a $79.00 price target.

Read More on BIIB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).